James E Flynn sold $10M of SPRY
owner at ARS Pharmaceuticals, Inc.. 563,270 shares at an average of $18.01, traded Nov 11, 2024, filed Nov 13, 2024.
Score components
- +12Role10% owner
- +25Trade size$10.1M at market
- +5Share of holdings soldSold 10% of holdings
- +15Cluster4 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -15.5%, 3m -17.4%, 6m -14.1%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193805-24-001348, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 11, 2024 | SOpen-market sale Class A Common Stockindirect: Through Deerfield Private Design Fund III, L.P. | -40,596 | $17.45 | $708k | 5,498,368 | Nov 13, 2024 |
| Nov 11, 2024 | SOpen-market sale Class A Common Stockindirect: Through Deerfield Private Design Fund IV, L.P. | -40,596 | $17.45 | $708k | 5,498,367 | Nov 13, 2024 |
| Nov 11, 2024 | SOpen-market sale Class A Common Stockindirect: Through Deerfield Private Design Fund III, L.P. | -223,632 | $18.15 | $4.1M | 5,274,736 | Nov 13, 2024 |
| Nov 11, 2024 | SOpen-market sale Class A Common Stockindirect: Through Deerfield Private Design Fund IV, L.P. | -223,632 | $18.15 | $4.1M | 5,274,735 | Nov 13, 2024 |
| Nov 12, 2024 | SOpen-market sale Class A Common Stockindirect: Through Deerfield Private Design Fund III, L.P. | -7,853 | $17.16 | $135k | 5,266,883 | Nov 13, 2024 |
| Nov 12, 2024 | SOpen-market sale Class A Common Stockindirect: Through Deerfield Private Design Fund IV, L.P. | -7,854 | $17.16 | $135k | 5,266,881 | Nov 13, 2024 |
| Nov 12, 2024 | SOpen-market sale Class A Common Stockindirect: Through Deerfield Private Design Fund III, L.P. | -9,554 | $17.77 | $170k | 5,257,329 | Nov 13, 2024 |
| Nov 12, 2024 | SOpen-market sale Class A Common Stockindirect: Through Deerfield Private Design Fund IV, L.P. | -9,553 | $17.77 | $170k | 5,257,328 | Nov 13, 2024 |
Related signals
Other insiders at ARS Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 34Weak | ARS Pharmaceuticals, Inc. | Kathleen D. Scott Chief Financial Officer | $188k 12,500 shares | -55% | |
| 41Moderate | ARS Pharmaceuticals, Inc. | Richard E Lowenthal PRESIDENT AND CEO | $724k 50,000 shares | -4% | |
| 31Weak | ARS Pharmaceuticals, Inc. | Sarina Tanimoto CHIEF MEDICAL OFFICER | $704k 50,000 shares | -4% | |
| 21Weak | ARS Pharmaceuticals, Inc. | Eric Karas Chief Commercial Officer | $255k 15,000 shares | -59% | |
| 50Moderate | ARS Pharmaceuticals, Inc. | James E Flynn owner | $14M 740,149 shares | -14% | |
| 21Weak | ARS Pharmaceuticals, Inc. | Eric Karas Chief Commercial Officer | $240k 15,000 shares | -66% | |
| 63Notable | ARS Pharmaceuticals, Inc. | Kathleen D. Scott Chief Financial Officer | $705k 50,000 shares | -87% | |
| 60Notable | ARS Pharmaceuticals, Inc. | Brent L Saunders director | $1.7M 120,000 shares | -100% | |
| 60Notable | ARS Pharmaceuticals, Inc. | Alexander A Fitzpatrick Chief Legal Officer | $1.5M 102,969 shares | -53% | |
| 5Weak | ARS Pharmaceuticals, Inc. | Laura Shawver director | $615k 50,002 shares | -19% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.